Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: Rationale and design of the ATHEROREMO-IVUS study

EuroIntervention

Volumn 10, Issue 8, 2014, Pages 953-960

  De Boer, Sanneke P M ^a   Cheng, Jin M ^a   Garcia Garcia, Hector M ^a   Oemrawsingh, Rohit M ^a   Van Geuns, RobertJan ^a   Regar, Evelyn ^a   Zijlstra, Felix ^a   Laaksonen, Reijo ^b   Halperin, Eran ^c   Kleber, Marcus E ^d,e   Koenig, Wolfgang ^f   Boersma, Eric ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TEL AVIV UNIVERSITY   (Israel)

^d LURIC Study Nonprofit LLC   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Association study; Atherosclerosis; Biomarkers; Genomewide; Intravascular ultrasound; Nearinfrared; Prognosis; Spectroscopy

Indexed keywords

BIOLOGICAL MARKER; LIPID; SPHINGOLIPID;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTERY CATHETERIZATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; COHORT ANALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; FOLLOW UP; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOME; HEART DISEASE; HISTOPATHOLOGY; HUMAN; INCIDENCE; INTRAVASCULAR ULTRASOUND; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OBSERVATIONAL STUDY; PATIENT REFERRAL; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDY; STABLE ANGINA PECTORIS; BLOOD; CORONARY ARTERY DISEASE; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; GENETICS;

ACUTE CORONARY SYNDROME; ANGINA, STABLE; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIPIDS; PLAQUE, ATHEROSCLEROTIC; SPHINGOLIPIDS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84920148501     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJY13M08_01     Document Type: Article

References (33)

1. Murray C, Lopez A. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard School of Public Health on behalf of the World Health Organization and The World Bank. 1996.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-26.
3. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol. 2004;13:125-38.
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
5. Libby P. Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol. 2006;98:3Q-9Q.
6. Wykrzykowska JJ, Garcia-Garcia HM, Goedhart D, Zalewski A, Serruys PW. Differential protein biomarker expression and their time-course in patients with a spectrum of stable and unstable coronary syndromes in the Integrated Biomarker and Imaging Study-1 (IBIS-1). Int J Cardiol. 2011;149:10-6.
7. Oemrawsingh RM, Lenderink T, Akkerhuis KM, Heeschen C, Baldus S, Fichtlscherer S, Hamm CW, Simoons ML, Boersma E; CAPTURE investigators. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart. 2011;97:1061-6.
8. Nair A, Margolis MP, Kuban BD, Vince DG. Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. EuroIntervention. 2007;3:113-20.
9. Garcia-Garcia HM, Mintz GS, Lerman A, Vince DG, Margolis MP, van Es GA, Morel MA, Nair A, Virmani R, Burke AP, Stone GW, Serruys PW. Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention. 2009;5: 177-89.
10. Garcia-Garcia HM, Costa MA, Serruys PW. Imaging of coronary atherosclerosis: intravascular ultrasound. Eur Heart J. 2010;31:2456-69.
11. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, LopezSendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Osterspey A, Tamargo J, Zamorano JL; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341-81.
12. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909-45.
13. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent STsegment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054.
14. Serruys PW, GarciaGarcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A. Effects of the direct lipoproteinassociated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172-82.
15. Ekroos K, Chernushevich IV, Simons K, Shevchenko A. Quantitative profiling of phospholipids by multiple precursor ion scanning on a hybrid quadrupole timeofflight mass spectrometer. Anal Chem. 2002;74:941-9.
16. Merrill AH Jr, Sullards MC, Allegood JC, Kelly S, Wang E. Sphingolipidomics: highthroughput, structurespecific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods. 2005;36:207-24.
17. Stahlman M, Ejsing CS, Tarasov K, Perman J, Boren J, Ekroos K. Highthroughput shotgun lipidomics by quadrupole timeofflight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:2664-72.
18. Ejsing CS, Duchoslav E, Sampaio J, Simons K, Bonner R, Thiele C, Ekroos K, Shevchenko A. Automated identification and quantification of glycerophospholipid molecular species by multiple precursor ion scanning. Anal Chem. 2006;78:6202-14.
19. Jung HR, Sylvanne T, Koistinen KM, Tarasov K, Kauhanen D, Ekroos K. High throughput quantitative molecular lipidomics. Biochim Biophys Acta. 2011;1811:925-34.
20. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
21. Erhardt L, Herlitz J, Bossaert L, Halinen M, Keltai M, Koster R, Marcassa C, Quinn T, van Weert H. Task force on the management of chest pain. Eur Heart J. 2002;23:1153-76.
22. Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M, Sonnenschein K, Regar E, van der Ent M, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT. The unrestricted use of paclitaxe-lversus sirolimuseluting stents for coronary artery disease in an unselected population: oneyear results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol. 2005;45:1135-41.
23. Calvert PA, Obaid DR, O'Sullivan M, Shapiro LM, McNab D, Densem CG, Schofield PM, Braganza D, Clarke SC, Ray KK, West NE, Bennett MR. Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging. 2011;4:894-901.
24. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364: 226-35.
25. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ. Unrestricted utilization of sirolimuseluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109:190-5.
26. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664-72.
27. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108:1772-8.
28. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13-8.
29. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:126275.
30. Lusis AJ. Atherosclerosis . Nature. 2000;407:233-41.
31. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166-76.
32. Garcia-Garcia HM, Costa MA, Serruys PW. Imaging of coronary atherosclerosis: intravascular ultrasound. Eur Heart J. 2010;31:2456-69.
33. Brugaletta S, GarciaGarcia HM, Serruys PW, GomezLara J, de Boer S, Ligthart J, Witberg K, Simsek C, van Geuns RJ, Schultz C, Duckers HJ, van Mieghem N, de Jaegere P, Madden SP, Muller JE, van der Steen AF, Boersma E, van der Giessen WJ, Zijlstra F, Regar E. Distance of lipid core-rich plaques from the ostium by NIRS in nonculprit coronary arteries. JACC Cardiovasc Imaging. 2012;5:297-9.